| Symbol | SLGL |
|---|---|
| Name | SOL-GEL TECHNOLOGIES LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 7 GOLDA MEIR STREET,WEIZMANN SCIENCE PARK, NESS ZIONA, 7403650, Israel |
| Telephone | +972 89313429 |
| Fax | — |
| — | |
| Website | https://www.sol-gel.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001684693 |
| Description | Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The companys product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Additional info from NASDAQ: |
Opaleye Management Inc. 🟢 acquired 1.7K shares of Sol-Gel Technologies Ltd. (SLGL) at $73.89 Transaction Date: Jul 13, 2026 | Filing ID: 033354
Read moreOpaleye Management Inc. 🟢 acquired 1.7K shares of Sol-Gel Technologies Ltd. (SLGL) at $71.99 Transaction Date: Jul 01, 2026 | Filing ID: 031991
Read moreNew Form SCHEDULE 13G/A - Sol-Gel Technologies Ltd. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001178913-26-003148 <b>Size:</b> 10 KB
Read moreOpaleye Management Inc. 🟢 acquired 1.6K shares of Sol-Gel Technologies Ltd. (SLGL) at $64.43 Transaction Date: May 20, 2026 | Filing ID: 025013
Read moreOpaleye Management Inc. 🟢 acquired 3.4K shares of Sol-Gel Technologies Ltd. (SLGL) at $67.98 Transaction Date: May 12, 2026 | Filing ID: 023056
Read moreNew Form SCHEDULE 13G/A - Sol-Gel Technologies Ltd. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001493152-26-021483 <b>Size:</b> 22 KB
Read moreNew Form SCHEDULE 13D/A - Sol-Gel Technologies Ltd. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001178913-26-002124 <b>Size:</b> 8 KB
Read moreOpaleye Management Inc. 🟢 acquired 39.7K shares of Sol-Gel Technologies Ltd. (SLGL) at $72.00 ($2.9M) Transaction Date: Mar 24, 2026 | Filing ID: 012354
Read moreNew Form 424B5 - Sol-Gel Technologies Ltd. <b>Filed:</b> 2026-03-24 <b>AccNo:</b> 0001178913-26-001626 <b>Size:</b> 429 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06050122 | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on… | Phase3 | Gorlin Syndrome | Active_Not_Recruiting | 2024-03-17 | 2026-10-01 | ClinicalTrials.gov |
| NCT05675501 | Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and … | Phase1 | Papulopustular Rosacea | Completed | 2020-06-10 | 2021-07-15 | ClinicalTrials.gov |
| NCT04308395 | Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (… | Phase3 | Basal Cell Nevus Syndrome | Terminated | 2020-06-03 | 2021-07-14 | ClinicalTrials.gov |
| NCT04155190 | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Pe… | Phase2 | Recurrent Basal Cell Carcinoma | Terminated | 2019-12-20 | 2021-04-23 | ClinicalTrials.gov |
| NCT04059523 | MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 | Phase1 | Acne Vulgaris | Completed | 2019-06-27 | 2020-02-06 | ClinicalTrials.gov |
| NCT03703310 | Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Pers… | Phase3 | Basal Cell Nevus Syndrome | Completed | 2019-02-19 | 2020-12-28 | ClinicalTrials.gov |
| NCT03761784 | A Study of S6G5T-3 in the Treatment of Acne Vulgaris | Phase3 | Acne Vulgaris | Completed | 2018-12-21 | 2019-12-31 | ClinicalTrials.gov |
| NCT03727074 | Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (… | Phase3 | Actinic Keratosis (AK) | Completed | 2018-12-21 | 2019-12-19 | ClinicalTrials.gov |
| NCT03761810 | A Study of S6G5T3 in the Treatment of Acne Vulgaris | Phase3 | Acne Vulgaris | Completed | 2018-12-14 | 2019-10-23 | ClinicalTrials.gov |
| NCT03564145 | A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea | Phase3 | Papulopustular Rosacea | Terminated | 2018-09-12 | 2019-11-13 | ClinicalTrials.gov |
| NCT03564119 | A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea | Phase3 | Papulopustular Rosacea | Completed | 2018-06-21 | 2019-06-10 | ClinicalTrials.gov |
| NCT03448939 | A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea | Phase3 | Papulopustular Rosacea | Completed | 2018-06-18 | 2019-05-24 | ClinicalTrials.gov |
| NCT02842021 | Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory… | Phase2 | Tinea Pedis | Terminated | 2016-09-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02661958 | Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of … | Phase2 | Acne Vulgaris | Completed | 2016-05-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT00940992 | A Study of DER 45-EV Gel to Treat Rosacea | Phase2 | Rosacea | Completed | 2012-01-01 | 2013-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Patidegib Topical Gel with no active patidegib | Other | Phase PHASE3 | Gorlin Syndrome | ACTIVE_NOT_RECRUITING | NCT06050122 |
| Patidegib Topical Gel | Other | Phase PHASE3 | Gorlin Syndrome | ACTIVE_NOT_RECRUITING | NCT06050122 |
| Patidegib Topical Gel, Vehicle | Other | Phase PHASE2 | Recurrent Basal Cell Carcinoma | TERMINATED | NCT04155190 |
| Patidegib Topical Gel, 2% | Other | Phase PHASE2 | Recurrent Basal Cell Carcinoma | TERMINATED | NCT04155190 |
| S5G4T-2 | Other | Phase PHASE3 | Papulopustular Rosacea | COMPLETED | NCT03448939 |
| S5G4T-1 | Other | Phase PHASE3 | Papulopustular Rosacea | COMPLETED | NCT03448939 |
| S6G5T-8 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-7 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-6 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-5 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-1 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-3 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| Retin-A® 0.1% Cream | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT04059523 |
| S6G5T-3 | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT04059523 |
| Vehicle | Other | Phase PHASE3 | Actinic Keratosis (AK) | COMPLETED | NCT03727074 |
| Efudex® | Other | Phase PHASE3 | Actinic Keratosis (AK) | COMPLETED | NCT03727074 |
| 5-FU Cream | Other | Phase PHASE3 | Actinic Keratosis (AK) | COMPLETED | NCT03727074 |
| S2G6T-4 | Other | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S2G6T-3 | Other | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S2G6T-2 | Other | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S2G6T-1 | Other | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S5G4T-1 | Other | Phase PHASE3 | Papulopustular Rosacea | TERMINATED | NCT03564145 |
| S5G4T-2 | Other | Phase PHASE3 | Papulopustular Rosacea | COMPLETED | NCT03564119 |
| S5G4T-1 | Other | Phase PHASE3 | Papulopustular Rosacea | COMPLETED | NCT03564119 |
| S6G5T-8 | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03761810 |
| S6G5T-3 | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03761810 |
| S6G5T-8 | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03761784 |
| S6G5T-3 | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03761784 |
| Encapsulated Benzoyl Peroxide Cream | Other | Phase PHASE1 | Papulopustular Rosacea | COMPLETED | NCT05675501 |
| Patidegib Topical Gel, Vehicle | Other | Phase PHASE2 | Recurrent Basal Cell Carcinoma | TERMINATED | NCT04155190 |
| Patidegib Topical Gel, 2% | Other | Phase PHASE2 | Recurrent Basal Cell Carcinoma | TERMINATED | NCT04155190 |
| Patidegib Topical Gel, Vehicle | Other | Phase PHASE3 | Basal Cell Nevus Syndrome | COMPLETED | NCT03703310 |
| Patidegib Topical Gel, 2% | Other | Phase PHASE3 | Basal Cell Nevus Syndrome | COMPLETED | NCT03703310 |
| Patidegib Topical Gel, 2% | Other | Phase PHASE3 | Basal Cell Nevus Syndrome | TERMINATED | NCT04308395 |
| Patidegib Topical Gel with no active patidegib | Other | Phase PHASE3 | Gorlin Syndrome | ACTIVE_NOT_RECRUITING | NCT06050122 |
| Patidegib Topical Gel | Other | Phase PHASE3 | Gorlin Syndrome | ACTIVE_NOT_RECRUITING | NCT06050122 |
| Patidegib Topical Gel with no active patidegib | DRUG | Phase PHASE3 | Gorlin Syndrome | ACTIVE_NOT_RECRUITING | NCT06050122 |
| Patidegib Topical Gel | DRUG | Phase PHASE3 | Gorlin Syndrome | ACTIVE_NOT_RECRUITING | NCT06050122 |
| Encapsulated Benzoyl Peroxide Cream | DRUG | Phase PHASE1 | Papulopustular Rosacea | COMPLETED | NCT05675501 |
| Retin-A® 0.1% Cream | DRUG | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT04059523 |
| Efudex® | DRUG | Phase PHASE3 | Actinic Keratosis (AK) | COMPLETED | NCT03727074 |
| 5-FU Cream | DRUG | Phase PHASE3 | Actinic Keratosis (AK) | COMPLETED | NCT03727074 |
| Patidegib Topical Gel, Vehicle | DRUG | Phase PHASE2 | Recurrent Basal Cell Carcinoma | TERMINATED | NCT04155190 |
| Patidegib Topical Gel, 2% | DRUG | Phase PHASE3 | Basal Cell Nevus Syndrome | TERMINATED | NCT04308395 |
| S5G4T-2 | DRUG | Phase PHASE3 | Papulopustular Rosacea | COMPLETED | NCT03564119 |
| S5G4T-1 | DRUG | Phase PHASE3 | Papulopustular Rosacea | TERMINATED | NCT03564145 |
| S2G6T-4 | DRUG | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S2G6T-3 | DRUG | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S2G6T-2 | DRUG | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S2G6T-1 | DRUG | Phase PHASE2 | Tinea Pedis | TERMINATED | NCT02842021 |
| S6G5T-8 | DRUG | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT03761810 |
| S6G5T-7 | DRUG | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-6 | DRUG | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-5 | DRUG | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-1 | DRUG | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT02661958 |
| S6G5T-3 | DRUG | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT04059523 |
| Vehicle | DRUG | Phase PHASE3 | Actinic Keratosis (AK) | COMPLETED | NCT03727074 |
| DER 45 EV | DRUG | Phase PHASE2 | Rosacea | COMPLETED | NCT00940992 |